Nintedanib to reduce nosebleeds in adults with HHT
Treatments studied
Part of Blood & lymphatic, Ear, nose & throat, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join the study and sign informed consent
- You’re 18 or older
- You have a confirmed HHT diagnosis (genetic mutation or meeting HHT criteria)
- Your nosebleeds are moderate to severe, based on a severity score
- Brain imaging shows no certain blood-vessel problem (no cerebral arteriovenous malformation)
- You cannot be pregnant or breastfeeding (for people who could become pregnant, you must use reliable birth control as instructed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce bleeding in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
Hear when a new Telangiectasia, Hereditary Hemorrhagic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.